Therapeutic options for patients with myelofibrosis in blast phase

Leukemia Research
J MascarenhasRonald Hoffman

Abstract

Myelofibrosis (MF) is a clonal stem cell disorder with the potential to transform to acute leukemia, referred to as myelofibrosis in blast phase (MF-BP). The outcome of patients with MF-BP is grave with a median survival of only 2.7 months. MF-BP is largely refractory to conventional chemotherapy and intensive induction therapy fails to have a significant impact with a median survival of 3.9 months. Eleven consecutive patients were treated at our institution with MF-BP over a 2-year period. Eligible patients with an available donor received an allogeneic stem cell transplant (ASCT) and those that were not eligible or without a donor were treated with Decitabine (DEC). The median time for follow up for the entire group was 9 months (range 5-21 month). At 9 months (range 5-45 months), 67% of the patients treated with DEC were alive and at 20 months (range 9-23 months), 53% of patients treated with ASCT remain alive. Reduced intensity conditioning allogeneic stem cell transplantation (RIC-ASCT) is a viable option that offers the potential for prolonged survival and the possibility of cure for patients with MF-BP. DEC is a tolerable outpatient chemotherapeutic regimen for MF-BP patients ineligible for transplant and deserves furthe...Continue Reading

References

Dec 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonUNKNOWN International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards
Jan 13, 2009·British Journal of Haematology·Alexey V DanilovKenneth B Miller

❮ Previous
Next ❯

Citations

Dec 10, 2013·Hematology·Olatoyosi Odenike
Jan 1, 2014·Leukemia Research·Srdan VerstovsekNeil P Shah
Sep 6, 2014·Best Practice & Research. Clinical Haematology·John Mascarenhas
Sep 6, 2014·Best Practice & Research. Clinical Haematology·Magnus BjörkholmÅsa Rangert Derolf
Dec 18, 2014·Proceedings of the National Academy of Sciences of the United States of America·Raajit RampalRoss L Levine
Apr 3, 2012·British Journal of Haematology·Donal P McLornanClaire N Harrison
Nov 26, 2010·The Mount Sinai Journal of Medicine, New York·John Mascarenhas, Ronald Hoffman
May 28, 2014·British Journal of Haematology·Marina KremyanskayaRonald Hoffman
Feb 11, 2015·Bone Marrow Transplantation·R TamariR Hoffman
Dec 29, 2016·Blood·Alessandro M Vannucchi, Claire N Harrison
Nov 4, 2017·Current Hematologic Malignancy Reports·Kristen Pettit, Olatoyosi Odenike
Oct 26, 2018·Current Hematologic Malignancy Reports·Bing LiRaajit K Rampal
Sep 13, 2019·Expert Opinion on Investigational Drugs·Georgina S Daher-ReyesKaren W L Yee
Dec 25, 2013·Current Opinion in Hematology·Raajit Rampal, John Mascarenhas
May 21, 2020·Blood·Andrew J DunbarRoss Levine
Oct 3, 2013·Expert Review of Hematology·Claire HarrisonSrdan Verstovsek
Jul 8, 2016·Expert Review of Hematology·Kristen Pettit, Olatoyosi Odenike
Apr 15, 2014·Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine·Norio Komatsu
Apr 25, 2019·International Journal of Molecular Sciences·Alessandra IurloUmberto Gianelli
Sep 4, 2019·Oncology Research and Treatment·Panagiotis T DiamantopoulosNora-Athina Viniou

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.